We are a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas™ program is our primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer’s disease and other vascular disorders. Our secondary focus is TGF-beta Shield™, a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX).

Our Product Development

NexVas™ Plaque Regression (NexVas PR) is a technology platform for the development of drugs that increase ApoA-I to reduce the risk of cardiovascular diseases. Our lead drug RVX-208 is currently in a Phase 1b/2a clinical trial.

NexVas™ Vascular Inflammation (NexVas VI) is a preclinical technology for the development of drugs that target molecular markers of inflammation.

NexVas™ Alzheimer's Disease (NexVas AD) is a technology in Phase 1 for the development of drugs that enhance ApoA-I for stabilization and regression of Beta Amyloid Plaque.   

ReVas™ is a discovery stage technology for the development of therapeutics to be used with medical devices for the treatment of cardiovascular diseases. ReVas is partnered with Medtronic Inc. 

TGF-beta Shield™ is a preclinical technology for the treatment of grievous proliferative diseases, such as cancer and fibrotic conditions.